[[Lupus Nephritis]]

_Multisystem inflammatory autoimmune disease with a broad spectrum of 臨床表現 in association with antinuclear antibody (ANA) production_

流行病學 (_Lancet_ 2014;384:1878)

* Prevalence 15–50/100,000; predominantly affects women 2nd to 4th decade

* ♀:♂ ratio = 8:1; African American:Caucasian ratio = 4:1

* Complex genetics; some HLA association; rarely C1q & C2 deficiency

Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria

![](https://i.imgur.com/w91UgC8.png)
![](https://i.imgur.com/S16TwzB.png)

[*](part0013.html#st16)Expert opinion, not dx criteria for SLE: ≥4/17 SLICC criteria, including ≥1 臨床& ≥1 immunologic, _or_ bx proven SLE nephritis with ⊕ ANA or anti-ds-DNA (_Arth Rheum_ 2012;64:2677)

![](https://i.imgur.com/di0cKLS.png)

Workup

* Autoantibodies: ANA, if ⊕ → ✔ anti-ds-DNA, anti-Sm, anti-Ro, anti-La, anti-U1-RNP

* CBC, APLA (⊕ in 20–40%; ACL, B2GP1, lupus anticoagulant), total complement, C3 & C4

* Lytes, BUN, Cr, U/A, urine sed, spot microalb:Cr ratio or 24-h urine for CrCl and protein

* If ↓ GFR, active sediment, hematuria, or proteinuria (>0.5 g/dL) → renal bx to guide Rx

![](https://i.imgur.com/zUjBqv9.png)

![](https://i.imgur.com/nFbkWGB.png)

(_Ann Rheum Dis_ 2010;69:2083; _NEJM_ 2004;350:971 & 2005;353:2219 & 2011;365:1886)

Prognosis (_Arth Rheum_ 2006;54:2550; _Rheum [Oxford]_ 2016;55:252)

•5-y survival rate >90%, 10-y survival rate >80%

•Leading causes of morbidity and mortality: **infection**, **renal failure**, neurologic and cardiovascular events; thrombotic complications (_Medicine_ 2003;82:299)

Drug-induced lupus (DLE) (_Drug Saf_ 2011;34:357; _Curr Opin Rheumatol_ 2012;24:182)

•Many drugs: **procainamide**, **hydralazine**, penicillamine, minocycline, INH, methyldopa, quinidine, chlorpromazine, diltiazem, **anti-TNF** (esp. infliximab), interferons

•Abrupt onset; generally mild disease with arthritis, serositis, skin disease; renal dx, malar and discoid rash rare; prevalence ♀:♂ = 1:1

•⊕ Anti-histone (95%) (may be ⊖ in anti-TNF); ⊖ anti-ds-DNA (often ⊕ in anti-TNF cases, even without 表現 of DLE) & ⊖ anti-Sm; normal complement levels

•Usually reversible within 4–6 wk after stopping medication